# TRAF6

## Overview
TRAF6 is a gene that encodes the TNF receptor-associated factor 6, a multifunctional adaptor protein that plays a critical role in various cellular signaling pathways. As an E3 ubiquitin ligase, the TRAF6 protein is involved in the regulation of immune responses, bone metabolism, and cellular signaling processes. It is characterized by a complex structure that includes a RING domain, zinc fingers, and a trimeric C-terminal domain, which are essential for its function in signal transduction and protein interactions (Chung2024Molecular; Guven2023Structural). TRAF6 is integral to the activation of key signaling pathways, such as NF-κB and MAPK, influencing immune cell function and osteoclast differentiation (Dainichi2019Immune; Lamothe2007Sitespecific). Mutations or dysregulation of TRAF6 are associated with various pathological conditions, including cancer, immune deficiencies, and bone disorders, highlighting its significance in both health and disease (Weisz2017Homozygous; Starczynowski2011TRAF6).

## Structure
TRAF6 (TNF receptor associated factor 6) is a protein characterized by its complex molecular structure, which includes several distinct domains. The primary structure of TRAF6 consists of 522 amino acids, with a molecular weight of approximately 59.4 kDa (Guven2023Structural). The N-terminal region of TRAF6 includes a RING domain, a linker helix, and three zinc fingers, which are crucial for its function as an E3 ubiquitin ligase (Guven2023Structural; Guven2023Structurala). The RING domain is involved in ubiquitin-ligase activity and DNA interaction, while the zinc fingers follow a conserved Sheet-Loop-Sheet-Helix-Loop pattern, interacting with zinc ions to maintain structural integrity (Guven2023Structural; Guven2023Structurala).

The tertiary structure of TRAF6 is stabilized by these zinc interactions, with specific cysteine and histidine residues forming the zinc fingers (Guven2023Structural). The protein forms a dimeric structure in its N-terminal region, with key residues such as Lys67, Gln82, Arg88, and Phe118 in the RING domain, and Phe122 in the linker region, mediating dimerization (Guven2023Structural; Guven2023Structurala).

In terms of quaternary structure, TRAF6 can form a trimer, particularly in its C-terminal domain, which is involved in receptor interactions and self-association (Chung2024Molecular; Biswas2019Structure). This trimeric formation is facilitated by conserved trimerization loops and is crucial for its function in signal transduction pathways (Chung2024Molecular). Post-translational modifications, such as ubiquitination, are essential for TRAF6's role in immune response and cellular signaling (Guven2023Structurala).

## Function
TRAF6 (TNF receptor-associated factor 6) is a critical adaptor protein involved in several signaling pathways that regulate immune responses and bone metabolism in healthy human cells. It functions as an E3 ubiquitin ligase, facilitating the formation of K63-linked polyubiquitin chains, which are essential for activating downstream signaling molecules such as IκB kinase (IKK) and NF-κB, key regulators of the immune response (Dainichi2019Immune; Lamothe2007Sitespecific). TRAF6 is involved in the signaling pathways of the TNF receptor superfamily and the IL-1 receptor/Toll-like receptor superfamily, playing a pivotal role in osteoclastogenesis and immune cell activation (Lamothe2007Sitespecific; Lomaga1999TRAF6).

In the immune system, TRAF6 is crucial for the activation of NF-κB and MAPK pathways, influencing the function and maturation of dendritic cells, macrophages, and T cells (Dainichi2019Immune; Kobayashi2004The). It also plays a role in the production of reactive oxygen species in macrophages, which is important for intracellular bacterial killing (Dainichi2019Immune). TRAF6 is active in both the cytoplasm and nucleus, impacting processes such as T-cell activation and osteoclast differentiation, which are vital for maintaining bone homeostasis and immune function (Lomaga1999TRAF6; Walsh2015Tumor).

## Clinical Significance
Mutations and alterations in the TRAF6 gene are associated with several diseases and conditions. In lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), TRAF6 is frequently amplified and overexpressed. This amplification is linked to enhanced cell proliferation and tumor growth, suggesting that TRAF6 acts as an oncogene in these cancers (Starczynowski2011TRAF6). 

TRAF6 deficiency in mice leads to osteopetrosis, a condition characterized by overly dense bones due to defective osteoclast function. This is because TRAF6 is crucial for RANKL-dependent osteoclast differentiation and activation (Weisz2017Homozygous; Lomaga1999TRAF6). In humans, a homozygous deletion involving TRAF6 results in severe combined immune deficiencies (SCID) and an atypical form of osteopetrosis, highlighting its role in bone metabolism and immune function (Weisz2017Homozygous).

TRAF6 is also implicated in hypohidrotic ectodermal dysplasia (HED), a condition marked by defective development of skin appendages such as sweat glands and hair follicles. TRAF6-deficient mice exhibit phenotypes similar to HED, including the absence of sweat glands and impaired hair follicle development (Naito2002TRAF6). These findings underscore the importance of TRAF6 in various physiological processes and its potential involvement in disease pathogenesis.

## Interactions
TRAF6 is an adaptor protein that engages in numerous interactions with other proteins, playing a pivotal role in various signaling pathways. It interacts with the ubiquitin-conjugating enzyme Ubc13 and the Ubc-like protein Uev1A to catalyze the synthesis of K63-linked polyubiquitin chains, which are crucial for activating kinases such as IKK and MAPK (Walsh2015Tumor). TRAF6 also interacts with IRAK1, IRAK2, and IRAK-M in the IL-1R/TLR signaling pathway, facilitating the assembly of the TAK1 activation complex, which is essential for IKK and MAP kinase activation (Wu2003TRAF6).

TRAF6 forms complexes with proteins like T6BP, which specifically associates with TRAF6 through its coiled-coil region, and this interaction is induced by IL-1 in a ligand-dependent manner (Ling2000T6BP). TRAF6 also interacts with RanBPM, which suppresses TRAF6-induced activation of the NF-κB pathway by inhibiting its activation and auto-ubiquitination (Wang2011The).

In the context of TCR-mediated T cell activation, TRAF6 associates with the C-terminus of MALT1 and is indirectly recruited through caspase-8, which is important for initiating IKK/NFκB signaling (Walsh2015Tumor). These interactions highlight TRAF6's role in immune cell signaling and its involvement in both protective and pathogenic inflammation.


## References


[1. (Naito2002TRAF6) Asuka Naito, Hisahiro Yoshida, Eri Nishioka, Mizuho Satoh, Sakura Azuma, Tadashi Yamamoto, Shin-ichi Nishikawa, and Jun-ichiro Inoue. Traf6 -deficient mice display hypohidrotic ectodermal dysplasia. Proceedings of the National Academy of Sciences, 99(13):8766–8771, June 2002. URL: http://dx.doi.org/10.1073/pnas.132636999, doi:10.1073/pnas.132636999. This article has 144 citations.](https://doi.org/10.1073/pnas.132636999)

[2. (Wu2003TRAF6) Hao Wu and Joseph R. Arron. Traf6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. BioEssays, 25(11):1096–1105, October 2003. URL: http://dx.doi.org/10.1002/bies.10352, doi:10.1002/bies.10352. This article has 242 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bies.10352)

3. (Chung2024Molecular) Molecular Basis for the Unique Specificity of TRAF6. This article has 60 citations.

[4. (Wang2011The) Lan Wang, Chengbo Fu, Yingbin Cui, Yunfei Xie, Yuhe Yuan, Xin Wang, Hong Chen, and Bing-Ren Huang. The ran-binding protein ranbpm can depress the nf-κb pathway by interacting with traf6. Molecular and Cellular Biochemistry, 359(1–2):83–94, July 2011. URL: http://dx.doi.org/10.1007/s11010-011-1002-3, doi:10.1007/s11010-011-1002-3. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11010-011-1002-3)

[5. (Ling2000T6BP) Lei Ling and David V. Goeddel. T6bp, a traf6-interacting protein involved in il-1 signaling. Proceedings of the National Academy of Sciences, 97(17):9567–9572, August 2000. URL: http://dx.doi.org/10.1073/pnas.170279097, doi:10.1073/pnas.170279097. This article has 60 citations.](https://doi.org/10.1073/pnas.170279097)

[6. (Dainichi2019Immune) Teruki Dainichi, Reiko Matsumoto, Alshimaa Mostafa, and Kenji Kabashima. Immune control by traf6-mediated pathways of epithelial cells in the eime (epithelial immune microenvironment). Frontiers in Immunology, May 2019. URL: http://dx.doi.org/10.3389/fimmu.2019.01107, doi:10.3389/fimmu.2019.01107. This article has 66 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2019.01107)

[7. (Weisz2017Homozygous) M. Weisz Hubshman, L. Basel‐Vanagaite, A. Krauss, O. Konen, Y. Levy, B.Z. Garty, P. Smirin‐Yosef, I. Maya, I. Lagovsky, E. Taub, D. Marom, D. Gaash, K. Shichrur, S. Avigad, L. Hayman‐Manzur, A. Villa, C. Sobacchi, M. Shohat, I. Yaniv, and J. Stein. Homozygous deletion of <scp>rag1</scp>, <scp>rag2</scp> and 5′ region <scp>traf6</scp> causes severe immune suppression and atypical osteopetrosis. Clinical Genetics, 91(6):902–907, March 2017. URL: http://dx.doi.org/10.1111/cge.12916, doi:10.1111/cge.12916. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cge.12916)

[8. (Biswas2019Structure) Ria Biswas, Nilkanta Chowdhury, Sima Biswas, Riya Roy, and Angshuman Bagchi. Structure based virtual screening of natural products to disrupt the structural integrity of traf6 c-terminal domain homotrimer. Journal of Molecular Graphics and Modelling, 93:107428, December 2019. URL: http://dx.doi.org/10.1016/j.jmgm.2019.08.005, doi:10.1016/j.jmgm.2019.08.005. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jmgm.2019.08.005)

[9. (Kobayashi2004The) Takashi Kobayashi, Matthew C. Walsh, and Yongwon Choi. The role of traf6 in signal transduction and the immune response. Microbes and Infection, 6(14):1333–1338, November 2004. URL: http://dx.doi.org/10.1016/j.micinf.2004.09.001, doi:10.1016/j.micinf.2004.09.001. This article has 102 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.micinf.2004.09.001)

[10. (Starczynowski2011TRAF6) Daniel T. Starczynowski, William W. Lockwood, Sophie Deléhouzée, Raj Chari, Joanna Wegrzyn, Megan Fuller, Ming-Sound Tsao, Stephen Lam, Adi F. Gazdar, Wan L. Lam, and Aly Karsan. Traf6 is an amplified oncogene bridging the ras and nf-κb pathways in human lung cancer. Journal of Clinical Investigation, 121(10):4095–4105, October 2011. URL: http://dx.doi.org/10.1172/jci58818, doi:10.1172/jci58818. This article has 138 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci58818)

[11. (Lamothe2007Sitespecific) Betty Lamothe, Arnaud Besse, Alejandro D. Campos, William K. Webster, Hao Wu, and Bryant G. Darnay. Site-specific lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of iκb kinase activation. Journal of Biological Chemistry, 282(6):4102–4112, February 2007. URL: http://dx.doi.org/10.1074/jbc.m609503200, doi:10.1074/jbc.m609503200. This article has 310 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m609503200)

12. (Guven2023Structural) Structural Characterization of TRAF6 N-terminal for Therapeutic Uses. This article has 0 citations.

[13. (Lomaga1999TRAF6) M. A. Lomaga, W.-C. Yeh, I. Sarosi, G. S. Duncan, C. Furlonger, A. Ho, S. Morony, C. Capparelli, G. Van, S. Kaufman, A. van der Heiden, A. Itie, A. Wakeham, W. Khoo, T. Sasaki, Z. Cao, J. M. Penninger, C. J. Paige, D. L. Lacey, C. R. Dunstan, W. J. Boyle, D. V. Goeddel, and T. W. Mak. Traf6 deficiency results in osteopetrosis and defective interleukin-1, cd40, and lps signaling. Genes &amp; Development, 13(8):1015–1024, April 1999. URL: http://dx.doi.org/10.1101/gad.13.8.1015, doi:10.1101/gad.13.8.1015. This article has 1024 citations.](https://doi.org/10.1101/gad.13.8.1015)

[14. (Walsh2015Tumor) Matthew C. Walsh, JangEun Lee, and Yongwon Choi. Tumor necrosis factor receptor‐ associated factor 6 (<scp>traf</scp>6) regulation of development, function, and homeostasis of the immune system. Immunological Reviews, 266(1):72–92, June 2015. URL: http://dx.doi.org/10.1111/imr.12302, doi:10.1111/imr.12302. This article has 326 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/imr.12302)

[15. (Guven2023Structurala) Omur Guven, Belgin Sever, Faika Başoğlu-Ünal, Abdulilah Ece, Hiroshi Tateishi, Ryoko Koga, Mohamed O. Radwan, Nefise Demir, Mustafa Can, Mutlu Dilsiz Aytemir, Jun-ichiro Inoue, Masami Otsuka, Mikako Fujita, Halilibrahim Ciftci, and Hasan DeMirci. Structural characterization of traf6 n-terminal for therapeutic uses and computational studies on new derivatives. Pharmaceuticals, 16(11):1608, November 2023. URL: http://dx.doi.org/10.3390/ph16111608, doi:10.3390/ph16111608. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ph16111608)